GenSight Biologics Reports Full Year 2019 Financial Results and provides an Outlook on 2020

GenSight Biologics announces presentation of bilateral visual recovery from GS010 (LUMEVOQ™) Phase III trials at the 46th annual meeting of NANOS

GenSight Biologics Reports its Cash Position as of December 31, 2019 and Provides Operational Update

GenSight Biologics Announces its 2020 Financial Calendar

GenSight Biologics Announces the Filing of its 2018 Universal Registration Document

GenSight Biologics obtains €15 million in financing through a bond issuance from Kreos Capital and a reserved capital increase from Sofinnova and 3SBio

GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history

The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France

GenSight Biologics Reports its Cash Position as of September 30, 2019 and Provides Operational Update

GenSight Biologics reports evidence of GS010 DNA transfer to contralateral eye of primates unilaterally injected with GS010 Gene Therapy